Ascus Biosciences, a San Diego, CA-based deep science animal health and nutrition company, raised $46m in Series B funding.
The round was led by Temasek, with participation from Anterra Capital, Formation 8 and Cavallo Ventures (the venture capital arm of Wilbur-Ellis), and additional support from various angel investors.
The company intends to use the funds to continue expanding its customer sales and servicing teams, advance new and existing products in its product pipeline and continue refining its core technology platform and intellectual property foundation.
Led by Michael Seely, chief executive officer, Ascus Biosciences uses its proprietary technology platform to resolve the complexities in the native microbial communities living in highly productive and healthy animals. From these curated insights, native microorganisms are selected and isolated from animal samples and developed into products.
The company has multiple microbial solutions in development, with some already in sales mode from dairy, poultry, beef feedlot, equine, to companion species.